Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Ashish Kamat MD

Ashish M. Kamat MD

Professor of Urologic Oncology and Wayne B. Duddlesten Professor of Cancer Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Ashish M. Kamat is a Tenured Professor of Urology and Holder of the Wayne B. Duddlesten Professorship in Cancer Research at M.D. Anderson Cancer Center in Houston, TX. Dr. Kamat served as the Director of the MD Anderson Urologic Oncology Fellowship from 2005-2016. He is currently President of the International Bladder Cancer Group (IBCG) and Co-President of the International Bladder Cancer Network (IBCN). He is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, and organ-sparing techniques. Dr. Kamat’s research focuses on efforts to develop novel therapies and identifying predictors of response to therapy.

Recent Contributions to PracticeUpdate:

  1. Outcomes of BCG Treatment in Patients With Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease
  2. Radical Cystectomy and Chemotherapy in Patients With Non-Metastatic and Metastatic Plasmacytoid Bladder Cancer
  3. Impact of Histological Variants on Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
  4. Treatment of High-Grade Non–Muscle-Invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations vs Reduced Number and Standard Dose of BCG Instillations
  5. Occult Nodal Metastases in Patients Downstaged to Non–Muscle-Invasive Disease Following Neoadjuvant Chemotherapy
  6. Poor Prognosis of Node-Positive Bladder Cancer Treated With Neoadjuvant Chemotherapy

Recently Updated